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Introduction: Tumour necrosis factor alpha (TNFa) is a pleiotropic cytokine 
which has both beneficial and deleterious effects. It has previously been 
shown in our laboratory that TNFa can mimic ischemic preconditioning (IPC). 
However, the signalling pathways involved in this protection remain 
incompletely understood. One potential protective pathway involves the 
generation of reactive oxygen species (ROS), which are known to be 
activated by TNFa. 
Hypothesis: It was therefore hypothesized that TN Fa-induced cytoprotection 
requires the generation of ROS. In addition, it was postulated that this ROS 
generation originates in the mitochondria. 
Methods: ~C12 myotubes, subjected to a simulated ischemiclreperfusion 
insult, were preconditioned with either a short period of hypoxia (IPC) or by a 
low dose of TNFa (O.5ng/ml). Cell viability was assessed using the propidium 
iodide technique and the trypan blue exclusion test. ROS scavengers were 
added to investigate the role of ROS in the protection conferred by TNFa. 
ROS generation was evaluated using 2'7' -dichlorofluorescin diacetate 
(DCFH-DA) and flow cytometry. The source of ROS production was 
investigated with a fluorescent imaging technique, by co-staining with 
Mitotracker Red CM-H2XRos and DCFH-DA. In addition, the effect of TNFa 
on the bioenergetics of mitochondria was evaluated by investigation of 
respiratory parameters, proton leak, inner mitochondrial membrane potential 
and rate of ATP synthesis in isolated mouse heart mitochondria. 
Results: Both TNFa and IPC stimuli improved cell viability in cells subjected 
to simulated ischemia/reperfusion but this protection was lost in the presence 
of ROS scavengers. Exposure of C2C12 myotubes to TNFa was associated 
with an increase of ROS production that was abolished in the presence of 
ROS scavengers. The fluorescent imaging technique showed that the TNFa-
induced ROS appeared to be localised mainly within the mitochondria. 
Using isolated mouse heart mitochondria, it was demonstrated that exposure 
to TN Fa (O.5ng/ml) increased the proton leak and reduced the respiratory 
control index (RCI). In addition, TNFa de polarised the inner mitochondrial 
membrane and decreased the rate of ATP synthesis. However, the presence 
of ROS scavengers abolished the effect of TNFa on RCI and proton leak. 
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In conclusion, these results strongly suggest that TNFa-induced 
cytoprotection requires the generation of ROS, most likely originating in the 
mitochondria. Furthermore, the data obtained from isolated mitochondria 
demonstrated for the first time that TNFa had an effect on the bioenergetics 
of the mitochondria, dependent on the intra-mitochondrial ROS, but 
independent of its binding to its specific cell surface receptors. Further 
investigations are required to demonstrate whether this direct effect of TNFa 





1. The Concept of Preconditioning 
1.1 Introduction 
The World Health Organisation has stated that by the year 2020, the 
major cause of death world wide will be acute coronary occlusion or "heart 
attack" (see review1). At present, in the United States, 1.5 million people 
per year develop myocardial infarction and 500 000 will die from this. For 
more than 25 years many attempts have been made to reduce myocardial 
infarct size. Various drug therapies such as r:?r-blockers, calcium channel 
blockers and anti-inflammatory compounds have been used in this pursuit. 
However, their effectiveness in limiting the infarct size as an end effector 
is small? In order to prevent heart attacks it is of importance to understand 




The word "ischemia" is derived from the Latin terms, isch meaning "to hold 
back" and aemia meaning "blood", Ischemia consequently means a lack of 
blood. In the heart, an abnormal narrOwing of the coronary artery 
decreases the blood supply to the myocardium to cause ischemia, 
resulting in dysfunction and/or death of heart muscle cells (myocardial 
infarction).3 Ischemic heart disease plays an important role in the 
increasing epidemic of heart related deaths. Feuerstein et al4 reported that 
ischemic heart disease was responsible for a large part of cardiac failure. 
Animal studies demonstrated that once the myocardium becomes 
severely ischemic, restoration of blood flow (reperfusion) is a prerequisite 
for myocardial salvage.5 These studies also showed that reperfusion after 
an ischemic episode may be correlated with deleterious changes such as 
arrhythmias, enzyme release or severe intramyocardial haemorrhage.5 
These changes were termed "reperfusion injuries" as they generally 
occurred when blood flow was restored. However, the concerns about the 
clinical significance of these reperfusion injuries were put aside for many 
years by the results of clinical studies. It is only recently that it has been 
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demonstrated that reperiusion therapy may be more beneficial than the 
ischemic state. 
1.2.2 Heart preconditioning 
In 1986 Murry et al5 discovered an intrinsic mechanism of profound 
protection which they described as ischemic preconditioning. They 
showed that four cycles of 5 minutes of ischemia with intermittent 
reperfusion could limit the infarct size by 75%. This phenomenon has 
been recognized as the strongest form of in vivo protection against 
myocardial ischemic injury. In their experiment, Murry et al5 showed that 
the brief episodes of ischemia and reperfusion protected the heart 
(myocardium) against sub-lethal ischemia and this became known as 
classical preconditioning or the first window of protection. The 
preconditioned state is quite transient but very robust, lasting for up to 6 
hours. A delayed form of protection reappears within 24 hours of the 
preconditioning stimulus and lasts for up to 72 hours. This is referred to as 
the second window of protection (SWOP).6 Less robust than classical 
preconditioning, although more prolonged, swap occurs between 12 and 
72 hours after a preconditioning stimulus. More recently, a study 
demonstrated that induction of foetal anaemia during pregnancy could 
enhance a long term cardioprotection.7 This study introduced a possible 
new window of protection. 
1.3 Different preconditioning stimuli 
1.3.1 Ischemic preconditioning 
Ischemic preconditioning (IPC) requires a brief period of ischemia followed 
by a short period of reperfusion. Li et als showed that once a maximal 
response is achieved, further ischemic stimulation has no additional effect 
against reperfusion injures. Classically, to precondition a rat heart using 
the Langendorff perfusion model and considering the first window of 
protection, requires 2 cycles of 5 minutes coronary occlusion followed by 5 
minutes of reperfusion. 
1.3.2 Pharmacological preconditioning 
In 1991 Liu et al9 reported that stimulation of the adenosine A1 receptor 
could mimic ischemic preconditioning. Over the last ten years, many 
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studies have shown that any agonist of Gi coupled receptors could act as 
a preconditioning trigger. These include adenosine, acetylchOline, 
bradykinin, the opioids, angiotensin II and endorphin.10-15 A brief exposure 
to ethanol can also confer protection. 16 However, it should be noted that 
variable concentrations as well as different types of preconditioning 
triggers are required for different species. 
In 2000, Horton et al17 showed that a threshold must be reached in the 
heart with regard to the dose of stimulus used before the heart can be 
protected against further damage. Thus both the type of agent as well as 
the required concentration used to precondition, is critical. 
1.3.3 Remote preconditioning 
This form of preconditioning is the most poorly understood. In 1993 
Przyklenk et al18 reported in dogs that brief ischemia in one region of the 
heart could enhance cardioprotection in a remote region. It was 
hypothesised that during a preconditioning stimulus some compounds are 
released and could act as a preconditioning trigger in another part of the 
heart. Verdouw et al19 confirmed this hypothesis by showing that occlusion 
of a mesenteric artery in the rat could initiate heart protection. 
1.3.4 Other forms of preconditioning 
Several other non-receptor-triggered forms of preconditioning have been 
described. In a study done in the isolated rat heart it was reported that a 
short period of elevated Ca2+ could mimic ischemic preconditioning.2o In 
this same study, the protection could be abolished by verapamil, a calcium 
channel blocker. A transient period of heat stress (hyperthermia) can also 
confer cardioprotection,21 but the mechanisms of this preconditioning 
effect still remain to be elucidated. 
Other forms of preconditioning such as pacing, hypoxia and stretch of the 
myocardial fibres are most likely to induce their protection through release 
of receptor ligands due to negative energy balance.22-24 
1.4 Preconditioning Pathways 
1.4.1 Preconditioning and G-Protein Coupled Receptors 
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Thornton et al25 postulated that once the heart has been stimulated by a 
trigger, such as adenosine, the ligands activated receptor is thought to 
couple to pertussis toxin sensitive inhibitory GTP-binding proteins (Gi-
proteins) in order to transduce their signal. Schultz et al26 showed similar 
findings. These Gi-proteins can move freely within the lipid bilayer of the 
cel1.27 GDP is bound to the Gi-proteins in their inactive state but when the 
Gi proteins are stimulated, the bound GDP is released to bind to the GTP 
thus activating this protein. The original signal is amplified by the 
movement of these Gi-proteins throughout the cell and many downstream 
molecules are subsequently activated. The role of these Gi-proteins in 
preconditioning is controversial. Evidence both for28 and against25• 29 a 
protective role exists in the rat model. Sumeray et al30 performed 
experiments involving the blockade of the Gi-proteins in other animal 
models using pertussis toxin and they showed that the protection induced 
by ischemic preconditioning was attenuated. 
1.4.2 Triggers versus Mediators 
In order to understand the different pathways involved in preconditioning it 
is convenient to think in terms of triggers, mediators, and end-effectors. 
Somewhere in the signal transduction pathways between the trigger signal 
and the end-effector is a memory element that is set by the 
preconditioning protocol and keeps the heart in a preconditioned state. 
Any step which takes place after the prolonged ischemic insult (index 
ischemia) can be classified as a mediator as it only exerts its activity after 
the index ischemia has begun. This can also include the end-effectors 
where the signal for protection presumably terminates. Triggers are 
therefore those interventions occurring before the index ischemia, (see 
review1). Many authors consider the opening of the mitochondrial f<ATP 
channel as the end-effector.31 -34 However, the existence of the channel is 
under speculation as, to date, it has not been cloned. Recent research by 
Hausenloy et al131 demonstrated that if the mitochondrial permeability 
transition pore (mPTP) was kept closed at reperfusion, this afforded 
protection to the myocardium. Since effective inhibition of mPTP opening 
at reperfusion may provide protection against ischemialreperfusion injury, 
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the mPTP has been postulated by this group as the end effector in 
preconditioning. 
In ischemic preconditioning or with different pharmacological 
preconditioning mimetics, such as acetylcholine, bradykinin, opioids and 
ischemia a proposed trigger cascade involves the activation of 
phosphatidylinositol 3-kinase (PI3K) and protein kinase B (PKB). This 
activation results in a subsequent stimulation of nitric oxide synthase 
(NOS), protein kinase G (PKG), the mitochondrial potassium dependent 
ATP channel (m~TP) and reactive oxygen species (ROS). This cascade in 
tum, stimulates the activation of the protective kinases such as protein 
kinase C (PKC)35 (Figure 1). 
Some triggers can also act as mediators (eg: PI3K and Erk). 
IPC Pharmacological PC 
I membrane 
cytoplasm 
, Bradykinin OPiO~S ACh 
00 ~ G B~_Triggerph_ase 










+ Activate kinases 
ROS ---.... ~ and protect 
Adapted from Critz et ai, Vasc Pharmacol, 2005, 42: 201-209 
Figure 1-1: Proposed triggering cascade in classical preconditioning. Ischemic 
preconditioning (fPC), bradykinin, opioids and acetylcholine act as preconditioning stimuli 
to activate the protective pathway in classical preconditioning. 
IPC = ischemic preconditioning; PI3K = Phosphatidylinositol 3-kinase; AktJPKB = Protein 
kinase B; NOS = Nitric oxide synthase; PKG = Protein kinase G; mKATP = mitochondrial 
potassium adenosine triphosphate channel; ROS = reactive oxygen species 
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2. TNFo and cardiovascular preconditioning 
2.1 Definition 
Tumour necrosis factor alpha (TNFo) is a multifunctional cytokine that has 
been implicated in diverse physio and physiopathological events such as 
inflammation, cellular survival, growth, differentiation and apoptosis.36, 37 It 
was first discovered and described in tumour masses and belongs to a family 
of signalling molecules that exist as type" membrane proteins characterized 
by the C-terminus being extra-cytoplasmic.38 Two isoforms of TNF have been 
identified (TNFo and TNF~) and they share similar activities. The more 
abundant of the two peptides is TNFo and it is thought to be the peptide that 
mediates cardiac homeostasis. It achieves its various effects by binding to 
one of its cognate receptors TNFo Receptor 1 (TNFR 1) or TNFo Receptor 2 
(TNFR 2}.38 Both of these receptors are expressed in the myocardium.39 
Recently, a mitochondrial binding protein for TNFo (mTNFR) has been 
discovered.40 
2.2 TNFa and ischemiaJreperfusion 
The production of cardiac TNFo has been well documented during acute 
cardiac ischemia with or without reperfusion.36, 41 Controversy surrounds the 
role of TNFo as it has both beneficial and deleterious effects. Many authors 
have shown that there is a direct correlation between serum TNFo levels and 
the severity and progression of heart failure.42-44 Kubota et al45 demonstrated 
that mice which overexpress TNFo specifically in the heart develop 
myocarditis. However, in support of its beneficial role, Lecour et al46 showed 
that TNFo can protect the heart in a dose and time-dependent manner. 
There is considerable support for TNFo in its protective role, depending on 
whether it is present for a short while in the myocardium or if it is present for 
a prolonged penod.47 Rabbits that had been given TNFo intravenously 24 
hours prior to a sustained ischemic insult showed improved contractile 
function and a decrease in the secretion of lactate dehydrogenase.48 The 
free radical scavenger. manganese superoxide dismutase (MnSOD) was 
also shown to be increased with the TNFo pre-treatment. This upregulation 
of MnSOD. possibly through transactivation of the nuclear transcription 
factor B (NFkB). may be a link to the pathway through which TNFo may offer 
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protection from ischemia, as NFkB is thought to upregulate a large number of 
cytoprotective genes.49 
Kurrelmeyer et also performed an elegant experiment in 2000 in which they 
illustrated that the loss of TNFa signalling resulted in a smaller capacity of 
the heart to resist an ischemic insult. The authors assessed infarct size 24 
hours' after subjecting TNFR1 and/or TNFR2 receptor knock out mice to an 
acute coronary occlusion. It was found that the infarct size in the combined 
knock out mouse was much larger than the infarct size of the wild type or 
when the TNFR1 or TNFR2 receptors were knocked out individually. In 
addition, when the receptors were knocked out individually, the infarct size 
was similar to that of the wild type mouse. These results suggested that 
TNFa signalling does confer protection, probably via the activation of both 
receptors. 
In contrast to these studies, Maekawa et al51 demonstrated in TNFa knock 
out mice that once reperfusion was initiated with its known inflammatory 
reaction, a deficiency in TNFa signalling resulted in a smaller myocardial 
infarction. In wild type control mice that underwent the same 
ischemialreperfusion protocol, anti· TNFa antibodies diminished the infarct 
size, thus confirming the putative deleterious effect of TNFa. In order to 
resolve these different outcomes one must surmise (1) that TNFa may 
promote an intrinsic cell survival programme in response to ischemia and (2) 
that this protective effect is attenuated by the inflammatory cascade induced 
by TNFa during reperfusion. Whether the effects of TNFa are deleterious or 
beneficial is probably dependent on the absolute levels within the distinct 
temporal periods of ischemia and reperfusion. 
2.3 TNFa and ischemic preconditioning 
TNFa is one of many inflammatory cytokines produced by the heart.52,53 In 
fact, the amount of TNFa per gram produced by the heart equals that 
produced either by the liver or the spleen. 52 Kapadia et al52 demonstrated 
that a wide variety of cells, including smooth muscle, endothelial and 
macrophages produce TNFa and surprisingly, that TNFa is also produced by 
cardiomyocytes themselves. Thus myocardial function can be affected by 
local TNFa production and the development of techniques to limit production 
of TNFa by the heart may improve post·ischemic myocardial function.36 In a 
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study done by Meldrum et al,36 it was shown that ischemia/reperfusion 
increases cardiac TNFo levels after 40 minutes of reperfusion. In the same 
experiment, IPC or pharmacological preconditioning with adenosine 
decreased this TNFo production. Adenosine has also been reported to exert 
cardioprotective effects through other mechanisms.54 
Smith et al55 showed that endogenous biosynthesis of TNFo occurred during 
ischemic preconditioning and that in ischemic preconditioning TNFo is 
required to attain a tolerant phenotype against ischemialreperfusion-induced 
infarction in the murine heart. From their data, it was concluded that TNFo is 
required to induce classical ischemic preconditioning and that it seems to 
confer this protection via the mitochondrial ~TP channel (m~TP). In 2002 
Lecour et al46 showed that TNFo in a low concentration acts as a 
preconditioning mimetic agent in the isolated rat heart and that the 
cardioprotective effects seem to signal through the m~TP as well as via a 
novel sphingolipid signalling pathway. 
2.4 TNFo and mechanisms of protection 
TNFo is responsible for the activation of multiple downstream signalling 
cascades including p38-Mitogen-activated protein kinase (MAPK). The major 
MAPKs found in cardiac tissue include the extracellular signal-regulated 
kinases (ERKlIERK2). the p46 and p54 c-Jun NH2.terminal kinase/stress-
activated protein kinases (JNKlSAPKs) and the 0 and P isoforms of p38.132 
p38 MAPK is known to act as a trigger in ischemic preconditioning.133 Tanno 
et al56 showed that a low concentration of TNFo could mimic ischemic 
preconditioning independently of p38MAPK activation. In contrast. higher 
non-protective doses of TNFo did activate p38MAPK. Recently. strong 
evidence has emerged to show that cardioprotection at reperfusion by TNFo 
is independent of activation of the prosurvival kinases. Akt (PKB) and ERK 
1/2.134 These data taken together suggest the possibility that multiple 
pathways may exist in relation to the trigger phase of preconditioning as has 
already been suggested by Vellon et al (see review 1). The signalling 
pathways involved in IPC and TNFo preconditioning may therefore diverge. 
Other pathways that TNFo is known to activate are NFKB57 and PKC (pro 
survival).3S· 58 caspases (anti-survival)59. 60 and the sphingolipids (either pro or 
anti survival).48. 61 In addition to PKC. involvement of tyrosine kinases in 
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ischemic preconditioning, TNFa-induced preconditioning and preconditioning 
with adenosine has been suggested in earlier studies, using tyrosine kinase 
inhibitors. 62~ It has also been demonstrated that a PKC-independent 
pathway, triggered by a tyrosine kinase mechanism could precondition. This 
study showed that TNFa was released in the heart after preconditioning by 
the activation of a disintegrin and metalloprotease (ADAM 17) and that infarct 
size in rabbit heart was reduced when ADAM 17 was activated.65 These 
authors speculate that cardiomyocytes are the primary source of TNFa in 
response to ischemic preconditioning. 
2.5 TNFa and the sphingolipid pathway 
Sphingolipids are a miscellaneous family of phospholipids and glycolipids 
which are built upon a long chain sphingoid backbone, generally 
sphingosine. Over the last few years, many studies provided evidence 
implicating the sphingolipids as second messengers in multiple signalling 
pathways initiated on binding of TN Fa to its receptor, TNFR1/p55.66-S8 




S1 phosphatase r 1 Sphingosine kinBse 
Sphingosine-1 
phosphate 
Figure 1-2: Schematic of sphingolipid biochemistry. 
SMase = sphlngomyelinase; TNFR = TNFa receptor; S1P Phosphatase = 
sphingoslne-1-phosphate phosphatase. 
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Briefly, in the presence of the enzyme, ceramidase, the cerami de is 
activated to form sphingosine which can in tum be recycled back to 
ceramide in the presence of the enzyme, ceramide synthase, or forms 
sphingosine-1-phosphate in the presence of sphingosine kinase. 
TNFa, with its broad spectrum of properties has been postulated to 
mediate sphingolipid signalling in order to contribute to the cell survival 
program activated by preconditioning. TNFa when binding to its receptors 
leads to activation of sphingomyelinase (SMase) to form ceramide from 
sphingomyelin. The sphingomyelinases are present in sub-cellular sites. 
In 2002 Lecour et al46 showed that the protection afforded with TNFa and 
ischemic preconditioning was lost in the presence of N-
oleoyJethanolamine (NOE), an inhibitor of ceramidase. In addition, a 
recent study showed that the activation of sphingosine kinase played an 
important role in IPC.61 Interestingly, sphingolipids are involved in TNFa 
preconditioning, but are not known to play a role in the preconditioning 
that follows transient global ischemia, suggesting that the Signalling 
pathways involved may be divergent. 46 
2.6 TNFa and the mitochondria 
The mitochondria are very complex organelles found in the cytoplasm of all 
eukaryotic cells. An important function of the mitochondria is to convert 
energy found in nutrient molecules (substrates) and store it in the form of 
adenosine triphosphate (ATP).The cells utilise the ATP to provide energy for 
various enzymes to carry out a variety of cellular functions. 
A mitoChondrial binding protein for TNFa (mTNFR) has recently been 
discovered.40• 69 This finding suggests the presence of a pathway capable of 
delivering TNFa directly from the cell surface to the mitoChondria.40 Therefore 
the effect of TNFa may be due in part to a direct effect on mitochondria. In 
2003 Busquets et al69 demonstrated a dear uncoupling of the mitochondria 
with the addition of a low concentration of TNFa to isolated rat liver 
mitochondria. This would indicate that intracellular effects can be exerted by 
TNFa. In addition, mitoChondria derived reactive oxygen species have been 
implicated as pivotal Signalling molecules in the cellular response to 
preconditioning triggers.70, 71 
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3. Reactive Oxygen Species 
3.1 Definition 
Any species capable of independent existence that contains one or more 
unpaired electrons is termed a "free radical".72 Among the free radicals are 
the Reactive Oxygen Species (ROS). The most commonly used definition of 
ROS is that they consist of free radicals where the unpaired electron or 
electrons are in the oxygen orbital. When the free electron is in the nitrogen 
orbital, such as nitric oxide, this is also termed a free radical but it belongs to 
a group known as the Reactive Nitrogen Species (RNS). 
Examples of ROS are the hydroxyl radical rOH) and superoxide (~.). 
Hydrogen peroxide because of its rapid decomposition giving rise to ·OH and 
~. is regarded as a reactive oxygen species, but it is not a true one. 
Harmful chemicals may be formed when ROS react in order to gain or lose 
an electron. For many years the attention given to ROS was mainly focussed 
on their deleterious effects. ROS are strong oxidants and can damage other 
molecules and the cell structures of which they form a part. This damage can 
vary in magnitude and various intracellular defence mechanisms exist to 
neutralize or control the potentially destructive reactivity of ROS. Some 
defence mechanisms are simple molecules like vitamins E and C, while 
some are enzymes like superoxide dismutase (SOD), catalase and 
glutathione, (see revie~7). These compounds collectively act as ROS 
scavengers. 
3.2 Main Sources of ROS 
There are five main sources of ROS production within the cell: 
(i) Reduced nicotinamide adenine dinucleotide/nicotinamide adenine 
dinucleotide phosphate oxidase system (NAD(P)H) is the main source 
of ROS in vascular cells. This is a membrane associated enzyme I 
composed of five subunits, catalyzing the one-electron reduction of 
oxygen, using NADH or NADPH as the electron donor.73 
(ii) Xanthine oxidase (XO) is physiologically present in the heart where it 
catalyses hypoxanthine to xanthine and xanthine to uric acid, the two 
terminal steps of purine metabolism. Both these steps generate 
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superoxide. This excess ROS is central to the role of XO in heart 
failure.74 
(iii) Cyclo-oxygenase (COX) exists in two major isoforms, COX-1 and 
COX-2. COX-1 is present in most cells and is responsible for 
constitutive prostaglandin formation. COX-2 is induced in response to 
stress, which includes ROS?S, 76 
(iv) Nitric oxide (NO) is a regulatory gas that acts in many different ways in 
the cardiovascular system and is generated by the nitric oxide 
synthase (NOS) family of proteins. Three isoenzymes of NOS have 
been identified: the first is found in neuronal and epithelial cells, the 
second in cytokine-induced cells and the third in endothelial cells. The 
second isoform of NOS can be induced by lipopolysaccharide and 
cytokines in a multitude of different cells.77, 78 In addition, ROS can be 
formed in cardiomyocytes by the uncoupling of NOS which releases 
an electron that may combine with the oxygen radical to generate 
peroxynitrite, a powerful oxidant. 143 
(v) Mitochondrial ROS: There are at least nine known sites that are 
capable of generating superoxide anion, a progenitor of ROS, (see 
review79). Complex 1 of the mitochondrial electron transport chain 
(ETC) has been accepted as a major site of mitochondrial ROS 
production,80 and Complex III of the ETC has also been implicated as 
an important site in the generation of mitochondrial ROS. 
There are many different ways of detecting the presence of ROS. The most 
reliable method is electron spin resonance with the spin trapping technique in 
which the presence of unpaired electrons trapped within a stable molecule 
can be detected. Unfortunately, this technique is very complex and requires 
the use of an expensive machine. A less specific but more affordable 
technique to different research laboratories consists of the use of f/uorometric 
dyes such as 2'7' -dichlorofluorescin diacetate (DCFH-DA) which fluoresces 
when oxidized by ROS and emits a signal at a certain wavelength.81 -84 
3.3 ROS and ischemia/reperfusion 
A fascinating example of ROS-mediated damage is ischemialreperfusion 
injury. During ischemia, an organ not only suffers from lack of oxygen supply 
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but also from the ROS that are produced when oxygen is restored at 
reperfusion. Many studies have demonstrated that ischemia/reperfusion 
generates ROS, including hydroxyl radicals, superoxide anions and hydrogen 
peroxide.85 86 Studies have shown that these robust amounts of ROS which 
are present at reperfusion are thought to be deleterious.87-89 In 1997 Vanden 
Hoek et aloo perfonned a study on ventricular cardiomyocytes from chick 
embryos demonstrating that the generation of ROS induced during 
ischemia/reperfusion was decreased by the addition of two different ROS 
scavengers, MPG and phenanthroline, implicating ROS generation during 
ischemia prior to reperfusion. 
Woo et al91 have shown that ROS are important regulatory molecules 
implicated in the signalling cascade triggered by TNFa, although these 
events are not yet well characterised. 
3.4 ROS and ischemic preconditioning 
Evidence also exists that ROS may be involved in the protection afforded by 
fPC and phannacofogical preconditioning. In a study done in chick ventricular 
cardiomyocytes, it was demonstrated that the increased protection afforded 
by acetylcholine-induced preconditioning was abolished by N-2-
mercaptopropionyl-glycine (MPG), a ROS scavenger.81 In 2001, Forbes et 
af1 showed that preconditioning with diazoxide promoted the generation of 
ROS in cardiomyocytes and that N-acetyl-L-cysteine (NAC) , a ROS 
scavenger, was effective in attenuating the improvement in post-ischemic 
function and energetiCS. These experiments suggest that the ROS can be 
involved in protection when generated as a trigger mechanism. Previous 
studies tested the theory that preconditioning might be mediated by an 
increase in antioxidant defences. However, Chen et al,92 demonstrated that 
the addition of NAC during the preconditioning protocol abolished the 
protection. This suggested that ROS were protective. 
ROS can also act as triggers of IPC. Cleveland et al93 and Baines et al94 
demonstrated that the protection of IPC could be blocked by an infusion of 
dimethylthiourea. a ROS scavenger or by MPG, a diffusible ROS scavenger. 
The mechanism by which ROS precondition the myocardium has not yet 
been elucidated but it is known that they can activate G-proteins,95 protein 
kinases96 and ATP-dependent potassium channels.97-99 
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3.5 ROS and the mitochondria 
After more than 30 years of study, several important mechanistic details of 
mitochondrial ROS production have been revealed but the bigger picture still 
remains to be elucidated. The bulk of oxidative pathways are harboured in . 
the mitochondria. These pathways are packed with various redox carriers 
that theoretically can leak single electrons to oxygen, thereby converting it to 
the superoxide anion. Recent studies have implicated mitochondrial derived 
ROS as pivotal signalling molecules in the cellular response to 
preconditioning triggers.70• 71 
Studies regarding the mechanistic aspects of mitochondrial ROS generation 
were carried out by Boveris and Chance in 1973.100 They found that the 
mechanism of superoxide generation was located in Complex III of the 
electron transport chain (ETC). These findings were confirmed in 1980 by 
Grigolava et al.101 
A second source of ROS generation in the ETC has been proposed at 
Complex I but the precise nature of the site and its significance to the 
production of mitochondrial ROS remain obscure.102 Kushnareva et a1102 
showed that cytochrome-c release causes ROS production in a site proximal 
to the rotenone inhibitory site in complex I of the ETC. One of the earliest 
studies demonstrated that superoxide can be produced in the presence of 
NADH by Complex 1.103 Although Complex I has been widely accepted as a 
major source of mitochondrial ROS production,BO. 104-106 there are still many 
issues that need to be addressed. 
3.6 ROS and TNFa 
Many studies have shown that TNFo produces ROS in various cell 
Iines.107.109 These studies used high concentrations of TNFo which led to the 
ROS production and subsequent cytotoxicity. In these studies the major 
source of TNFo-induced ROS production has been identified as the 
mitochondria. Garcia-Ruiz et al,109 using high concentrations of TNFo, 
demonstrated that cerami de mediated the cytotoxicity of TNFo by increased 
generation of ROS in the mitochondria, principally at Complex III of the 
electron transport chain (ETC). Corda et al,11o using a low concentration of 
TNFo demonstrated a rapid mitochondrial production of ROS at the 
ubisemiquinone site (between Complex " and III) in human endothelial cells. 
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They showed that this effect occurs via a ceramide-dependent signalling 
pathway initiated by SMase. Evidence exists that TNFa can bind to a 
receptor on the inner mitochondrial membrane40 but whether it directly 





Classic ischemic preconditioning (IPC) is described as brief episodes of 
ischemiaJreperfusion which protect the myocardium from the damage 
induced by subsequent more prolonged ischemia. TNFa is a pleiotropic 
cytokine implicated in both beneficial (cell survival) and deleterious events 
including inflammation, growth and apoptosis.36•37 Recently it has been 
shown that in a dose and time-dependent manner, TNFa can mimic ischemic 
preconditioning.46 In addition, TNFa is known to produce intracellular 
reactive oxygen species (ROS) and the mitochondria have been identified as 
a major source of ROS production.109.11o 
Hypothesis 
In the present study, it was proposed that activation of 
TNFa-induced cytoprotection is mediated by ROS 
generation. In addition, it was postulated that these ROS 




Rgure 2-1: Schematic of proposed hypothesis. 
cytosol 
TNFa = tumour necrosis factor alpha; TNFR112 = tumour necrosis factor 
receptor 1 or 2; mTNFR = mltochoncklal tumour necrosis factor receptor; 
ROS = reactive oxwen species. TNFa can either bind to its cell surface 
receptors inducing ROS production in mitochondria or it can act independently 
of this pathway, binding directly to the mTNFR of isolated nitochondria, 
inducing intra-mitochondrial ROS production. 
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To evaluate this hypothesis, the following objectives were pursued: 
1. Using C~12 myotubes subjected to simulated ischemia/reperfusion, the 
cytoprotective effect of TN Fa was evaluated in the presence or absence of 
ROS scavengers. The production and the localisation of ROS within the 
mitochondria were measured using 2'7' -dichlorofluorescin diacetate dye 
and Mitotracker Red CM-H2XRos. 
2. Using isolated mouse heart mitochondria the effect of TNFo on the 
bioenergetics of the mitochondria in the presence or absence of ROS 






1. TNFa-induced cytoprotection is mediated via 
ROS 
1.1 Cell culture 
Skeletal muscle is able to undergo classical preconditioning using a 
mechanism which is virtually identical to that of the heart. 111A murine 
skeletal muscle cel/line, C2Cn, obtained from the European Col/ection of 
Cell Cultures (Centre for Applied Microbiology and Research, UK) was 
therefore chosen. These cells were sub cloned from mouse skeletal cells 
using hind limb muscle. 112 They are rapidly dividing myoblasts that can be 
differentiated into multinucleated myotubes, and are thus similar to 
cardiomyocytes. The tissue culture flasks do not require any prior coating 
in order for these cells to adhere. 
Cells were stored in cryovials in liquid nitrogen at -196°C and in order to 
grow the cells the cryovial was first thawed for 30-40 seconds in a 37°C 
water bath. The contents were carefully pipetted out into a 25 cm2 tissue 
culture flask containing 5 ml of fresh culture medium conSisting of 
Dulbecco's Modified Eagles Medium (DMEM); (Highveld Biological, RSA) 
supplemented with 10% Foetal Calf Serum (FCS); (Highveld Biological, 
RSA). Penicillin (1 %); (Highveld Biological, RSA) and Streptomycin (1 %); 
(Highveld Biological, RSA) were also added. The cells were placed in a 
5% C~ incubator maintained at 3rC and 95% humidity until the flask 
was 90-95% confluent when they were trypsinised with a Trypsin/EDTA 
solution made up in phosphate buffered saline (PBS), containing 0.25% 
trypsin(wlv);(Highveld Biological, RSA) and 0.2% EDTA(w/v);(Sigma, 
Germany). A sufficient volume of Trypsin/EDTA to cover the cell layer was 
added to the cells for 3 minutes at 37°C after which it was neutralized with 
double the volume of DMEM containing 10% FCS. The cell suspension 
was centrifuged for 5 minutes at 1000 rpm. The cell pellet was 
resuspended in a sufficient volume of medium to split into either 1:3 or 1 :4 
ratios depending on the size of flask to be used. When a sufficient number 
of flasks had been seeded for the experiment, these were allowed to 
reach 80% confluency before differentiation which was achieved by 
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changing the medium to DMEM containing 1 % Horse Serum (HS);(Sigma, 
Germany), penicillin (1 %) and streptomycin (1 %). The C>.!C12 myoblast 
cells differentiate into myotubes over a period of 3-4 days and are only 
used 8-10 days post differentiation. During this period, the cells were fed 
every second day using fresh DMEM with 1 % HS, penicillin (1 %) and 
streptomycin (1 %). 
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Figure 3-1: Schematic representation of preconditioning protocols 
In physiological ischemia, the pH decreases, potassium levels increase 
and metabolic activity is compromised. Therefore in order to simulate the 
ischemia which occurs in the heart, a simulated ischemic buffer with a low 
pH, a high content of KCI, and 2-Deoxy-d-Glucose (2-DG) is used. The 
addition of 2-DG prevents glycolysis, thereby subjecting the cells to 
metabolic inhibition and the pH of the buffer is reduced from 7.2 to 6.4. 
The protocol to simulate ischemia was adapted from Esumi et al113 and 
has been described previously for C2C12 myotubes.
32 In brief, the 
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simulated ischemic buffer contained in mM: 137 NaCl, 12 KCI, 0.5MgCI2. 
0.9 CaC12.20 Hepes. 20 2-Deoxy-d-Glucose (2-DG) adjusted to a pH of 
6.4. A Sanyo Multigas Incubator with 5% CO2, 94% N2. and 1 % Oz 
provided a hypoxic environment. All experiments were performed in 25 
cm2 tissue culture flasks. The protocol consisted of the following groups: 
A normoxic control group consisted of cells which were kept in their 
normal environment for the duration of the experiment but were subjected 
to the same number of washes with PBS as were the treated cells. 
In a simulated ischemic (SI) control group, the cells were washed twice 
with PBS before addition of buffer and incubation for 7 hours in the 
hypoxic incubator with SI buffer. pH 6.4. 
TN Fa-treated cells (recombinant murine TNFa, PeproTech, USA, 0.5ng/ml 
in DMEM with 1 % HS) were incubated for 30 minutes in the standard 5% 
C02 incubator. TNFa was washed out with two washes of PBS, fresh 
DMEM (1 %HS) was added and the cells were reincubated for 60 minutes 
in the standard 5% C~ incubator. After a further 2 washes with PBS the 
cells were incubated with SI buffer for 7 hours in the hypoxic incubator. 
In the IPC group the cells were incubated for 30 minutes in the hypoxic 
incubator in SI buffer, pH 6.2 without 2-DG, as we did not wish to inhibit 
glycolysis during IPC. This was followed by 2 washes with PBS and 
reincubation in DMEM (1 % HS) for 60 minutes in the standard 5% COz 
incubator. After a further 2 washes with PBS the cells were incubated with 
SI buffer for 7 hours in the hypoxic incubator. 
To demonstrate whether reactive oxygen species (ROS) were involved in 
the protective effect of TNFa, two ROS scavengers, N-acetyl-L-cysteine 
(NAC 30~M);(Sigma, Germany) or N-2-mercaptopropionyl-glycine (MPG 
1 O~M);(Sigma, Germany) were added to the cells 15 minutes prior to the 
addition of TNFa (0.5 ng/ml) and continued for the 30 minutes incubation 
with TNFa in the standard 5% CO2 incubator or, in the case of IPC. 15 
minutes in DMEM (1 % HS) in the standard 5% CO2 incubator followed by 
incubation with the SI buffer (no 2-DG. pH 6.2) for 30 minutes in the 
hypoxic incubator. Cells are then reincubated for 60 minutes in DMEM 
(1 % HS) in the standard 5% C~ incubator followed by 2 washes with 
PBS before incubating in SI buffer for 7 hours in the hypoxic incubator. 
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The ROS scavenger control groups consisted of NAC or MPG added for 
15 minutes in DMEM (1 % HS). The cells are washed twice in PBS and 
incubated in DMEM (1% HS) with NAC or MPG for 30 minutes in the 
standard incubator. After two further washes with PBS, cells are 
reincubated in fresh DMEM (1 % HS) for 60 minutes in the standard 
incubator, washed in PBS and incubated in SI buffer for 7 hours in the 
hypoxic incubator. 
1.3 Cell viability analysis 
1.3.1 Propidium Iodide 
Cell viability was evaluated using a flow cytometer (FACS Calibur, Becton-
Dickinson, USA) to measure the uptake of propidium iodide (PI);(Sigma, 
Germany) which is known to bind to DNA and become fluorescent. 82 
However, if the cell membrane is intact PI will not be able to enter the cell 
and translocate to the nucleus. Consequently it is used in 
immunofluorescent staining protocols to identify dead cells. Flow 
cytometry detects the presence of individual celfs that are held in a thin 
stream of fluid and passed through one or more laser beams causing the 
light to scatter and fluorescent dyes to emit light at various frequencies. 
Photomultiplier tubes (PMT) convert light to electrical signals and cell data 
is collected. Once the C2C12 myotubes had undergone the experimental 
protocol outlined above, the flasks were trypsinised and cells resuspended 
in their normal growth medium. PI (1.5IJM) was added and the cells 
reincubated for 5 minutes in the standard 5% CO2 incubator before 
analysis on the flow cytometer. PI fluorescence was measured in a 
population of 1 x 104 cells which was then analysed by means of 
CellQuest software. 
1.3.2 Trypan Blue 
The Trypan Blue exclusion technique for cell viability was also used. In 
this method trypsinised cells are resuspended in PBS and mixed with an 
equal volume of trypan blue (4IJM); (Sigma, Germany) which enters cells 
in which the membrane is not intact, dyeing them blue. Stained cells are 
loaded onto a Neubauer h aemocyto meter and evaluated by light 
microscopy. The ratio of blue cells, to grey cells or those in which cell 
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membranes are still intact is then calculated and expressed as a 
percentage. 
1.4 Respiratory parameters 
Consumption of oxygen during cellular respiration by the mitochondria is 
utilized for bioenergetic functions, the principal one being the conversion of 
ADP to A TP. A TP is used by enzymes to perform a wide range of cellular 
functions. In whole cells the respiration which occurs as a result of the 
utilisation of their endogenous substrates is termed State 2 respiration. In 
2001 Minners et af2 showed that IPC and pharmacological preconditioning 
increased cellular respiration prior to the index ischemia. It was decided for 
this study, to establish whether TNFa had a similar effect on State 2 
respiration in whole C2C12 myotubes, which would suggest that the cells were 
protected from ischemia by the TNFa stimulation. As MPG has been reported 
to have inconsistent effects on models of ischemia and reperfusion,144 N-tert-
Butyl-a-(2-sulfophenyl) nitrone sodium (2-SPBN), (Sigma, Germany) was 
chosen as a second ROS scavenger to confirm previous results with MPG. 
Two time points were examined: 
a) Immediately prior to the 7 hour simulated ischemic insult as shown in 
Figure 3-2. 
, 5tate 2 respiration 
Membrane Potential 
Normoxic Control 
Cell viability , 
7/ TNFa (0.5nglml) --1 TNF 51 t-n 
'I .~t IPC I hypoxia I 51 ..... 
'I 
T, 
TNFa + NAC or 2-SPBN I TNF I 51 7/ t-ii 
IPC +NAC or 2-SPBN I hypoxia I II 51 7l TI I-
*1 51 7/ I-NAC or 2-SPBN " 
16 min 30 min 60 min 7 hours I I I 
51=simulated ischemia 
IPC=ischemic preconditioning 
NAC (30 !-1M) or 2-SPBN (10 !-1M) 
Rgure3-2: Schematic representation of State 2, Membrane 
Potential and cell viability protocols immediately prior 
to thr simulated ischemia. 
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or 
b) Immediately after the full preconditioning protocol, with 7 hours of 
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Figure 3-3: Schematic representation of State 2, Membrane Potential 
and cell viability protocols after thr simulated ischemia. 
Respiration studies were perfonned using an Oxytherm respirometer 
equipped with a Clark-type electrode and a Peltier temperature control unit 
(Oxytherm, Hansatech, Norfolk, UK). The respirometer was calibrated using 
PBS and a temperature of 3rC was maintained throughout. 1 ml of PBS was 
then placed in the chamber and a baseline reading was taken to verify the 
calibration. 
Each experiment had a normoxic control. In the second set of experiments, a 
simulated ischemic control was included. In both sets of experiments, cell 
viability was measured using PI. Using the percentage viability obtained, 
respiration values from viable cells only were calculated by means of a factor. 
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After trypsinisation, cells were resuspended in PBS at a concentration of 2 x 
10scells/ml. 1x10s cells were added to the chamber and State 2 respiration 
was determined at the time pOints shown in Figure 3-2 and Figure 3-3. 
1.5 Inner Mitochondrial Membrane Potential Analysis 
Cells with a high energy requirement need to maintain their inner 
mitochondrial membrane potential for their performance. Relative changes in 
inner mitochondrial membrane potential have been widely measured by 
lipophilic fluorescent cations.114, 115 A variety of these cations are currently 
available. To assess mitochondrial uncoupling, the inner mitochondrial 
membrane potential was evaluated using 3,5',6,6'-tetrachloro-1, 1',3,3'-
tetraethyl benzimidazolyl-carbocyanine (JC-1). This dye exhibits potential-
dependent accumulation in mitochondria which is indicated by a fluorescence 
emission shift from green (525nm) (FL 1) to red (590nm) (FL2) after being 
excited at 488nm. A decrease in the red/green fluorescence intensity ratio 
therefore signifies mitochondrial depolarisation or a reduced membrane 
potential. To limit dye specific findings, use was made of a second cationic 
dye, Dihexyloxacarbocyanine iodide (DiOCs), which was excited at 488nm 
and the resultant fluorescence analysed at 525nm (FL 1).11s,117Propidium 
iodide (FL3) was added to exclude dead cells from the analysis, by the 
selection of only viable cells on the flow cytometer and gating these cells, 
using CellQuest software. As PI is excited at 525nm and emitted at 550nm to 
630nm, we were able to select the emission wavelength in order to 
compensate for the cross over in emission spectrums between FL 1, FL2 and 
FL3, using the software provided. 
Cells described in 1.4 above, were used to evaluate the inner mitochondrial 
membrane potential. JC-1 (Sigma, Germany) was dissolved in DMSO 
(0.25mM) and aliquots were stored at -20°C. DiOCs (Sigma, Germany) was 
dissolved in ethanol (1 mM) and aliquots were stored at -20"C. Membrane 
potential was evaluated at the end point in each set of experiments as 
follows: After the different treatments (see Figure 3-2 and Figure 3-3) the 
cells were trypsinised, counted and resuspended in PBS. A 400IJI aliquot was 
placed in a tube and 81J1 JC-1 (final concentration 51JM) added to the tube. 
The tube was incubated at 3rC for 10 minutes after which 41J1 PI (final 
concentration 1.5IJM) was added and the tube reincubated for a further 5 
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minutes. To a second tube containing 400~1 of the cell suspension, 4~1 
DiOC6 (final concentration 20nM) and 4~1 PI (final concentration 1.5~M) were 
added and the tube incubated for 5 minutes at 37°C. To validate appropriate 
responses to the dyes, the uncoupling agent carbonyl cyanide 3-
chlorophenylhydrazone (CCCP 0.1 ~M); (Sigma, Germany) or the 
hyperpolarising agent oligomycin (1.2~M); (Fluka, Germany) were incubated 
for 5 minutes with the cells. The cells were analysed on a f1uorometric 
analysis cell sorter (FACSCalibur, Becton Dickinson, USA) and the mean 
fluorescence was calculated for each sample. A" data were relative levels 
versus control. The remainder of the cell suspension was used for the 
respiration study as outlined in 1.4 above. 
1.6 Detection and quantification of ROS production 
A crucial Signalling step in the cell-protective phenomenon of 
preconditioning is the production of reactive oxygen species. 70, 92 TNFa is 
known to mimic preconditioning and also to produce ROS. For this study it 
was decided to investigate whether TNFa-induced ROS were involved in 
the cytoprotective pathway. Various methods have been developed for the 
detection of different types of free radicals including super oxide, hydrogen 
peroxide and peroxinitrite. 118 
In this study the 'fluorometric probe, 2'7' dichlorofluorescin diacetate 
(DCFH-DA); (Molecular Probes, USA) was used. The non-fluorescent 
DCFH-DA rapidly penetrates the cell membrane and is deacetylated by 
intrace"ular esterases. Alkaline and oxidative hydrolysis also plays a role. 
The non-fluorescent compound dichloronuorescin (DCFH) is formed and 
trapped in the cytosol where it is preferentially oxidised by hydrogen 
peroxide and superoxide to the fluorescent dichlorofluorescein (DCF). 
DCFH-DA was dissolved in DMSO to give a stock solution of 15mM and 
aliquots were stored at -20°C. 
C2C12 myotubes were trypsinised and resuspended in their normal growth 
medium after the preconditioning stimulus described in 1.2. DCFH-DA 
(5~M) was added and the myotubes reincubated at 37°C for 10 minutes. 
PI (1.5~M) was added and the cells reincubated for a further 5 minutes. 
The myotubes were divided into two equal aliquots. The first aliquot was 
used to give untreated baseline measurements for each time point, in 
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order to compensate for any background fluorescence generated by the 
growth medium, and the second aliquot was treated with TNFa (0.5ng/ml). 
DCF fluorescence was analysed every minute from zero to 3 minutes and 
thereafter at 5 minutes, 10 minutes, 15 minutes, 20 minutes 30 minutes, 
60 minutes and 120 minutes using a FACS Cali bur (Becton Dickinson, 
USA) flow cytometer. DCFH-DA is excited at 488nm and the fluorescein 
signal is analysed at 525nm (FL 1). PI was added to exclude dead cells 
'from the analysiS (FL3). Less than 5% of C2C12 myotubes were found to 
be PI positive. 1 x 104 PI negative cells were analysed in each sample. 
The fluorescence data was plotted on a histogram and the geometric 
mean calculated for each sample.119 The same experiments were 
repeated with the addition of the ROS scavenger, MPG. 
1.7 Source of ROS production after TNFa stimulation 
To determine whether the ROS produced by the addition of TN Fa to the C~12 
myotubes were generated by the mitochondria, the fluorescent dye, 
Mitotracker Red CM-H2XRos (M7513, Molecular Probes, USA) was used. This 
probe fluoresces only when it enters an actively respiring cell where it is 
oxidised to the fluorescent mitochondrion-selective probe and then 
sequestered in the mitochondria. This signal from this dye is excited at 488nm 
and emitted at around 600nm and can therefore be used in conjunction with 
DCFH-DA which is excited at 488nm and is emitted at 525nm. 
The C~12 cells were grown on coverslips and differentiated as described 
previously. The myotubes were then stained simultaneously with DCFH-DA 
(5IJM) and Mitotracker Red CM-H2XRos (1 OOnM) for 10 minutes at 3JOC. The 
coverslip was then placed on a glass slide and the cells were visualised 
using a Nikon Eclipse E400 fluorescent microscope at 60X magnification and 
fitted with a Nikon DMX1200 digital camera. Once a suitable field had been 
selected and the image captured using Simple PCI software (Compix Inc, 
Imaging systems, Pennsylvania, USA), 0.5ng/ml TNFa was added directly to 
the cells being visualised and the cells were monitored for ROS prodUction, 
with images being captured at 1 min, 3 min, 5 min and 10 min. These images 
were then superimposed over the image of the same field showing the 
mitochondria as stained with the DCFH-DA and mitotracker dye. Hydrogen 
peroxide was used as a positive control. 
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2. Effect of exogenous TNFo in Isolated Mouse Heart 
Mitochondria: role of ROS 
As a result of the data obtained using the C2C12 cell line and the discovery in 
recent years of a mitochondrial binding protein for TNFa, it was decided to 
investigate whether TNFa could have a direct effect on isolated heart 
mitochondria and whether this effect was mediated via activation of intra-
mitochondrial ROS. 
All animal studies performed were approved by the Animal Research Ethics 
Committee of the University of Cape Town, and followed the 
recommendations laid down in the Guide for the Care and Use of laboratory 
animals (NIH publication No. 85-23, revised 1996). 
2.1 Isolation of Mitochondria 
10-12 week old male Black 6 x 129 mice (25-30g) were anaesthetized with 
sodium pentabarbitone (50mg kg-1intra-peritoneally) and heparinised to 
prevent the blood clotting (25 International Units, intra-peritoneally). A 
sufficient depth of anaesthesia was achieved once the pedal reflex had 
disappeared. The heart was then rapidly excised and kept in ice-cold 
isolation buffer (0.18M KCI, 0.01M EDTA, pH to 7.4 with 2M Tris).12o The 
atria and connective tissue were trimmed off and the remaining ventricles 
minced on ice. The homogenate was rinsed until all visible blood had been 
eliminated (4 rinses with - 5X w/v ice-cold isolation buffer). After rinsing, the 
tissue was gently homogenized with a 5ml glass homogeniser (Tenbroek, 
Netherlands) and the homogenate centrifuged at 2930 rpm (Christ MK202, 
Germany) to eliminate the larger intracellular constituents. The supernatant 
was carefully transferred into a clean, cold tube and centrifuged at 4500 rpm 
to isolate the mitochondria.120 The resulting pellet was resuspended genUy in 
50IJI of ice-cold isolation buffer and was kept on ice for up to 3 hours. The 
protein content of the pellet was determined using the method of LOwry.121 
2.2 Lowry Protein Detennination 
Duplicate 1:200 dilutions of mitochondrial suspension were made using 
sterile distilled water. 1 ml of CTC reagent was added and the samples 
thoroughly mixed. After incubation for 10 minutes at room temperature, 0.5ml 
of Folin's Reagent (Merck, Germany) was added with continuous mixing as 
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the colour complex was formed immediately. The samples were incubated at 
room temperature for a further 30 minutes and then read at 750nm on a 
Varian 130 dual beam spectrophotometer. 
CTC reagent consisted of the following: 
Na2C03 (20%wlv) and CuS04.5H20 (0.2%wlv) to which an equal volume of 
dipotassium tartrate (O.4%wlv) was added. 
Folin-Ciocalteu's phenol reagent was diluted 1:6 with double distilled water 
before use. 
A standard curve, using bovine serum albumin (Sigma, Germany) diluted to 
provide a concentration range from 10 - 200tJg/ml was assayed in the same 
manner as the samples. 
2.3 Mitochondrial Respiration Studies 
There are four states of mitochondrial respiration or utilisation of oxygen, 
which are defined as follows: 
a) State1 is the respiration resulting from mitochondrial use of endogenous 
substrates. 
b) State 2 is that which occurs in the absence of ADP. 
c) State 3 is the respiratory state in which phosphorylation of ADP to ATP 
occurs and is where a considerable amount of oxygen is utilised. 
d) State 4 is reached when all ADP has been converted to ATP. 
Respiration studies were performed using an Oxytherm respirometer 
equipped with a Clark-type electrode and a Peltier temperature control unit 
(Oxytherm, Hansatech, NOrfolk, UK). The respirometer was calibrated using 
the mitochondrial incubation buffer (25mM Tris, 250mM Sucrose, 8.5mM 
KH2P04. pH to 7.4 with 2M Tris). All experiments were performed at 25°C. 
The respiration protocols are shown in Figure 3-4. 
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Figure 3-4: Schematic of respiration protocol. RS=ROSscavengers; 
SL=sphingolipid inhibitors. 
Isolated mitochondria were added to mitochondrial incubation buffer in the 
Oxytherm chamber, left to stabilise for 1 min and then substrate (1 OmM) was 
added. After 1 min, State 3 respiration was initiated by the addition of ADP 
(350IJM). Once State 4 was reached, oligomycin (1.2IJM) was added to 
achieve State 3b which was used to calculate the proton leak. The treated 
group had TNFa (O .5ng/ml) added 1 min after the substrate. 
A baseline reading of buffer alone was taken to verify the calibration of the 
Oxytherm respirometer. 251J1 of the mitochondrial suspension (isolated as in 
2.1) was then added to the 341111 of buffer and the plunger inserted. After 1 
minute, a second reading was taken to determine State 1 respiration after 
which 20IJI of glutamate (10mM) was added and State 2 respiration 
measured 1 minute later. State 2 respiration represents the utilization of the 
substrate in the absence of ADP. After stabilization, 141J1 of ADP (350IJM); 
(Roche, Germany) was added to trigger State 3 respiration. Conversion of 
ADP to ATP consumes a relatively large amount of oxygen during State 3. 
The mitochondria progressed to State 4 respiration in which all the ADP had 
been utilized and a steady state of respiration again occurred. 
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The following groups were considered in the protocol outlined in Figure 3-4: 
1) Untreated control mitochondria 
2) 0.5ng/ml TNFo - added 1 min after stabilization with glutamate 
3) TNFo + 30~M NAC 
4) TNFo +10 ~M 2-SPBN 
5) TNFo + 5~M NOE 
6) NAC 
7) 2-SPBN 
The ROS scavengers and sphingolipid inhibitors were added to the buffer 1 
minute prior to the addition of isolated mitochondria. 
The concentrations given are final concentrations within the chamber. 
2.4 Proton Leak 
The ATP synthase is specifically blocked by oligomycin. Therefore any 
oligomycin insensitive state 3 mitochondrial respiration which occurs will 
represent mitochondrial proton leak which is an in(lex of the state of 
mitochondrial uncoupling. 
To determine the rate of oligomycin induced mitochondrial proton leak, 
oligomycin (1.2~M) as well as an additional 14~1 ADP (100mM stock) was 
added immediately after State 4 respiration (Figure 3-4). State 3b is the 
oligomycin insensitive respiration. The percentage of proton leak can be 
calculated as a result of the ratio between State 3b respiration and State 3 
respiration. 
2.5 Respiratory Control Index (Rei) 
The respiratory control index (RCI) is a simple ratio of State 3 
respiration/State 4 respiration and is an index of the viability and coupling of 
the mitochondrial population. An RCI equal to or greater than 3 is an index of 
a good mitochondrial isolation. Therefore mitochondria which had an RCI of 
less than 3 were discarded in our experiments. 
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2.6 Mitochondrial Inner Membrane Potential 
The generation of mitochondrial ATP is dependent on the integrity of the 
inner mitochondrial membrane potential. This needs to be maintained in cells 
with high energy requirements such as the carrJiomyocyles. However, mild 
uncoupling of the mitochondria is thought to be protective. To observe 
whether TNFa depolarises the isolated mitochondrial inner membrane, JC-1 
(S,S:6,6'-tetrachloro-1, 1',3,3'-tetraethylbezimadazolyl-carbocyanine iodide) 
was used. JC-1 is one of the lipophilic fluorescent cations that have been 
widely used to measure relative changes in inner mitochondrial membrane 
potential. 114. 115 
JC-1 (2.5mM in DMSO) was diluted 1:100 in PBS. prewarmed to 3JOC and 
84~1 of this was added to 341 ~I mitochondrial incubation buffer containing 
25~1 mitochondrial suspension. 20~1 glutamate (10mM final concentration) 
and 14~1 ADP (350~M final concentration). The final concentration of the JC-
1 was thus 5~M. The suspension was kept at 3JOC for 5 minutes and then 
analysed on a Becton-Dickson F ACS (nuorescence activated cell sorter) 
Calibur flow cytometer. The JC-1 was excited at 488nm and the monomer 
signal (green) was emitted at 525nm (FL 1). Simultaneously. the aggregate 
signal (red) was emitted at 590nm (FL2). As a control. unstained 
mitochondria were analysed. After obtaining the readings for membrane 
potential, Carbonyl cyanide 3-chlorophenylhydrazone (CCCP) was added at 
a final concentration of 0.1 uM (20ul of a 1 ~M stock solution) in order to 
confirm that it was membrane potential and not mitochondrial volume or size 
being measured. 
A second potentiometric dye. DiOCa (3',3' -dihexyloacarbocyanine iodide) 
was used to confirm the results obtained with JC-1. A 1 mM stock solution 
was made up in ethanol. dispensed into Eppendorf tubes and stored at minus 
20°C. An aliquot was diluted 1 :1000 to yield a 1 ~M solution of which 40~I 
was added to the isolated mitochondria as for the JC-1. After 5 minutes at 
room temperature, the sample was analysed on the flow cytometer. DiOCa 
was excited at 488nm and the signal was emitted at 525nm (FL 1). Unstained 
mitochondria were again used as a control and CCCP was used to abolish 
the membrane potential after staining (0.1 ~M final concentration). 
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2.7 Rate of mitochondrial ATP synthesis 
The rate of ATP synthesis is the rate at which mitochondria phosphorylate 
ADP to ATP. By measuring this rate it can be seen which mitochondria are in 
a better bioenergetic state and more resilient to stress factors. 
For this study a modified method of Budnikov was used.122 In order to 
measure the amount of ADP that was phosphorylated to ATP over a timed 
period the following reaction was set up: 
The control was prepared as follows: 
898J .. 1I of synthesis buffer (final concentrations of: 150mM sucrose, 75mM 
KCI, 3IJM rotenone, 5mM KH2P04, 2.5mM MgCI2) was warmed to 25°C. 11J1 
of mitochondrial suspension (prepared as in 2.1) was added. After 30 
seconds of equilibration, 1001J1 succinate was added (final concentration 
10mM) and allowed to equiliprate for 60 seconds. 
TNFa (0.5ng/ml) was added to another identically prepared sample 
21J1 ADP (350IJM) was added to the control and TN Fa-treated mitochondria 
and the clock started immediately. A zero time sample of 51J1 of each was 
taken and thereafter for every 10 seconds up to 60 seconds. The 51J1 
samples were added directly into 501J1 cold 2.5% trichloroacetic acid to arrest 
the reaction and release the ATP. The solution was neutralized with 10IJI of 
1 M Tris base, and frozen at -80GC for later assay. 
The assay was carried out as follows: Duplicate 101J1 samples from each 
assay time point were added into separate wells of a 96 well plate. A 
standard curve consisted of serial dilutions of sodium ATP (Roche, Germany) 
from 10-5M to 10·eM and 101J1 aliquots were used in duplicate for the assay. 
1751J1 of double distilled water was added to each well. Firefly 
luciferinlluciferase assay reagent, FFL (FL-AAM); (Sigma, Germany) was 
prepared by adding 5ml of double distilled water to one vial. The vial was 
allowed to stand for up to 30 minutes to dissolve properly. The reagent was 
added to a Veritas Microplate Luminometer (Turner Biosystems, Sunnyvale, 
California, USA) and the 96 well plate inserted. 25111 of the FFL was added 
automatically by the luminometer to each well for the assay and the amount 
of relative light signal emitted was read, using the Veritas Software Rev 1.1. 
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Once the assay was completed, Graphpad Prism 3 was used to plot the log 
of relative light units (RLU) versus the concentration, The unknowns are then 
read off the standard curve by entering the log RLU's and allowing the 
programme to calculate the concentrations, 
2.8 Role of ROS and the sphingolipid pathway 
TNFa is known to stimulate the sphingolipid pathway and it has been shown 
previously that the cytoprotective effect of TNFa was abolished by NOE in 
the isolated perfused rat heart,46 In order to determine whether the 
sphingolipid pathway was mediated by TNFa-induced ROS in isolated 
mitochondria two inhibitors of this pathway were employed, imipramine, and 
N-oleoylethanolamine (NOE). Imipramine prevents TNFa activating 
endosomal acid sphingomyelinase (aSMase), thus inhibiting sphingomyelin 
from forming ceramide. NOE inhibits the enzyme ceramidase without which 
the ceramide cannot form sphingosine 
To determine whether NOE (Sigma, Germany) and imipramine (Sigma, 
Germany) could abrogate the effect of TNFa on the respiration, NOE or 
imipramine was added immediately prior to the mitochondria in the Oxytherm 
chamber and allowed to stabilise for 1 minute before adding TNFa 
(0.5ng/ml). After 5 minutes, State 2 respiration was measured. The same 
procedure as in 2.3 (see Figure 3-4) was then followed to obtain State 3 and 
State 4 respiration as well as the proton leak. 
Chemicals: Unless othetwise mentioned all chemicals used were obtained 
from Merck, Germany. 
3. Statistical Analysis 
Results were expressed as mean values ± standard error of the mean 
(s.e.m) and were analysed by One Way Analysis of Variance (Anova) with 
Tukey-Kramer Multiple Comparisons test, using GraphPad InStat version 
3.01 (GraphPad Software, San Diego, California, USA). Differences were 
considered statistically significant at values of p<0.05. When a comparision 




1. TNFa-induced cytoprotection is mediated by ROS 
1.1 TNFa induces cytoprotection in C2C12 myotubes 
a) Cell viability 
Cells were used 8-10 days post-differentiation, after reaching the 
mature myotube stage. 
C2C12 myotubes that were maintained in their normal environment for 
the full preconditioning protocol had a viability of 93±2% (PI technique) 
or 84±3% (Try pan blue exclusion test) respectively. Myotubes 
incubated for 7 hours in hypoxic buffer under hypoxic conditions 
(simulated ischemia, SI), showed a drastic reduction in viability to 
34±1 % (PI) or 24±6% (Trypan blue). Ischemic preconditioning protocol 
(lPC) improved myotube viability to 74±2% and 78±3% with PI and 
Trypan blue, respectively. Similarly TNFa used as a preconditioning 
mimetic improved the viability to 75±1 % (PI) and 81 ±2% (Trypan 
blue). (Figures 4-1 and 4-2). 




CTL Sl IPC TNFa 
Figure 4-1: Cell Viability (using Propidium Iodide technique) in C2C12 myotubes. Cell 
viability (expressed as a percentage) was dramatically reduced in cells subjected to 7hr 
simulated ischemia (Sf). Ischemic preconditioning (IPC) or TNFa (0. 5ng/ml) restored the cell 
viability. 
·p<o.001 versus SI, n = 6. 
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• Trypan Blue exclusion test 
* 
* 
CTL Sl IPC TNFa 
Figure 4-2: Cell Viability (using Trypan blue exclusion technique) in C2C12 myotubes. 
Cell viability (expressed as a percentage) was dramatically reduced in cells subjected to 7hr 
simulated ischemia (SI). Ischemic Preconditioning (IPC) or TNFa (0. 5nglml) restored the cell 
viability. 
*p<o. 001 versus SI, n :: 6. 
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b) Respiratory parameters 
State 2 respiration was evaluated immediately prior to the 7 hour 
simulated ischemic period or immediately post 7 hour simulated 
ischemia. 
• Pre-simulated ischemia analysis 
Prior to simulated ischemia, State 2 respiration was markedly 
increased in the IPe and TNFa groups compared to the normoxic 
control (1S.6±O.9 and 21.6±1.3 respectively versus control 





.- C» 1 e u 
.- C» Q.-
cnJl e .!!! 1 
N~ o 





IIPCITNij 6Omin~1 1 • SI 
* 
ell IPC lNFa 
Figure 4-3: State 2 respiration in C2C12 myotubes prior to the ischemic insult. Both 
ischemic preconditioning (fPC) and TNFa (O.5ng/ml) increase State 2 respiration of C2C12 
myotubes. State 2 respiration was expressed as nM of oxygen/million viable cells/min. 
*p<:O.01 versus control, n = 8. 
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• Post-simulated ischemia analysis 
Post 7 hour simulated ischemia, State 2 respiration in the simulated ischemic 
control was increased compared to the normoxic control (2S.8±O.9 versus 
S.2±O.S p<O.OS). State 2 respiration values for the IPC group and the TNFa 
group were restored to normoxic values (S.4±O.4 and 6.6±1.4 respectively 
versus normoxic control S.2±O.S). (Figure 4-4). 
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Figure 4-4: State 2 respiration in C2C12 myotubes immediately after the ischemic 
insult. State 2 respiration of the simulated ischemic group (SI) is markedly increased versus 
control. Both ischemic preconditioning (fPC) and TNFa (0. 5ng/ml) restore State 2 respiration 
to normoxic values. State 2 respiration was expressed as nM of oxygen/million viable 
cells/min. 
*p<O.05 versus control, n ~ B. 
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• Pre-ischemic analysis 
The inner membrane potential was evaluated both immediately 
prior to or immediately post 7 hours simulated ischemic insult. 
Both the IPC group and TN Fa-treated myotubes that were 
examined prior to the SI demonstrated a modest depolarisation 
of the membrane potential compared to the normoxic control, 
199±2 arbitrary units (AU.) and 24S±1 AU. respectively, versus 
control 281±2 AU., p<O.OS. (Figure 4-5) 
30 min ~I 7 hours IPCITNF I 60 min SI 7l r-I, 
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Figure 4-5: Membrane potential in C2C12 myotubes, using JC-1, prior to 7 hr S/. The 
IPC group shows a pronounced depolarisation immediately prior to the thr simulated 
ischemic insult (SI). The TNFa-treated group (0. 5ng/ml) demonstrated a modest 
depolarisation of the membrane. Membrane potential was measured in arbitrary units. 
*p<O.05 versus control, n = 8. 
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• Post- ischemic analysis 
After 7 hours of simulated ischemia, cells were depolarised versus the control 
group (174±7 A.U. and 232±6 A.U. respectively, p<O.05). Both IPC and TNFa 
restored the membrane potential to control values. (Figure 4-6) 
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Figure 4-6: Membrane potential of CZC12 myotubes, using JC-1 after 7hour simulated 
ischemia. The C2C12 myotubes which were subjected to thr simulated ischemia (SI) showed 
a robust depolarisation of their inner mitochondrial membrane. IPC and TNFa restored the 
membrane potential to normoxic values. Membrane potential was measured in arbitrary units 
(A. U.). 
*p<O.05 versus control, n = 8. 
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1.2 TNFa-induced cytoprotection is abolished with ROS scavengers 
a) Cell viability 
Two ROS scavengers, NAC and MPG were added to the 
preconditioning protocol 15 minutes prior to IPC or addition of TNFa. 
When used on their own, as preconditioning mimetics, both NAC and 
MPG had no protective effect. The viability for the normoxic, simulated 
ischemic, IPC and TNFa groups was similar to the values previously 
reported in Figure 4-1 and Figure 4-2. Addition of NAC to the 
preconditioning protocol reduced the viability from 85±1 % to 55±1 % 
for IPC and from 89±2% to 56±1 % for TNFa, p<O.001. Addition of 
MPG reduced the viability to 27±7% for IPC and 15±1 % for TNFa, 
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Figure 4-7: Effect of ROS sca'll'engers on the cytoprotective effect of fPC and TNFa 
(Propidium Iodide technique). Addition of N-acetyl-L-cysteine (NAC; 3OpM) or N-2-
mercaptopropionyl-glycine (MPG; 1o.f.lM) during the preconditioning stimulus reduced the 
viability of IPC and TNFa (D.5ng/ml) groups. Cell viability was expressed in percentage 
using Propidium Iodide technique. 
tp<D. 0.0.1 versus IPC; *p<D. 0.0.1 versus TNFa, n = 6. 
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Similar results were obtained using Trypan blue technique. Addition of NAC 
reduced the viability from 87±2% to 55±1% for IPC and from 79±1% to 
56±O.8% for TNFa, p<O.001. Addition of MPG reduced the viability to 
41.5±O.4% for IPC and 18.1±O.6% for TNFa, p<O.001. (Figure 4-8) 
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Figure 4-8: Effect of ROS scavengers on the cytoprotective effect of TNFa and IPC 
(Trypan Blue exclusion test). Addition of N-acetyl-L-cysteine (NAC; 301JM) or 2-N-
mercaptopropionyl-glydne (MPG; 101JM) during the preconditioning stimulus reduced the 
viability of IPC and TNFa (O.5ng/ml) groups. Cell viability was expressed in percentage using 
Trypan Blue exclusion technique. 
"#p<o.001 versus IPC; *p<0.OO1 versus TNFa, n = 6. 
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b) Respiratory parameters 
-c:: 
• Pre-ischemic analysis 
The presence of ROS scavengers abolished the increase in 
State 2 respiration previously observed with IPC or TNFa 
immediately prior to SI. Addition of NAC decreased the 
respiration from 1S.S±O.6 to S.7±O.3 for IPC and from 21.S±O.6 to 
8.S±1 for TNFa, p<O.01. The second ROS scavenger, 2-SPBN 
decreased the respiration to S.8±O.2 for IPC and 7.9±O.3 for 
TNFa, p<O.01 . (Figure 4-9) 
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Figure 4-9: Effect of ROS scavengers on State 2 respiration in C2C12 myotubes 
measured immediately before the ischemic insult. The addftion of NAC (30IlM) or 2-
SPBN (10j.JM) abolishes the increase in State 2 respiration induced by IPC or TNFa 
(O.5ng/ml). The ROS scavengers alone have no effect on State 2 respiration. State 2 
respiration was expressed as nM of oxygenlmilfion viable celfs/min. 
'l-p4J.01 versus IPC; "p<.O.01 versus TNFa, n = 8. 
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• Post-ischemic analysis 
Immediately after 7 hours SI, State 2 respiration in the simulated ischemic 
group was significantly raised to 25.8±O.95 versus the normoxic control of 
4.8±O.5 p<O.05. State 2 respiration of both IPC and TNFa groups was 
restored to control group values. Addition of NAC reversed this effect from 
4.5±O.6 to 9.1±O.9 for IPC, p<O.05 and 5.4±O.5 to 16.1 ±O.8, for TNFa, 
p<O.05. Addition of 2-SPBN reduced State 2 respiration to 12.2±O.8 for IPC 
and 17.3±O.9 for TNFa, p<O.05. (Figure 4-10) 
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Figure 4-10: Effect of ROS scavengers on State 2 respiration in CZC12 
myotubes immediBtely after the ischemic insult. State 2 respiration of the 
simulated ischemic group (SI) is markedly increased. Both ischemic preconditioning (IPC) 
and TNFa restore State 2 respiration to normoxic values. The addition of NAC (3O/JM) or 2-
SPBN (1O/JM) significantly increases the respiration in the IPC and TNFa groups. NAC and 
2-SPBN had no effect when administered on their own (not shown). 
State 2 respiration was expressed as nM of oxygen/million viable cells/min. 
i-p<Cl-05 versus IPC n ~8 *p<Cl05 versus TNFa, .p<O.OO1 versus control, n ~ 8. 
1.3 Detection and quantification of ROS production 
The detection and quantification of ROS was performed using the 
fluorometric probe 2'7'dichlorofluorescin diacetate (DCFH-DA) and a flow 
cytometer. An untreated control was run for each time point as endogenous 
ROS is present in cells. The results were normalised against the controls. A 
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short burst of ROS was observed lasting on average for 3 minutes after the 
addition of TNFa, a maximum increase of 4S±1% being observed at 2 
minutes. Addition of MPG decreased the amount of ROS generated in the 
untreated cells (1S±1 %). When MPG was added to the TNFa-treated cells, 
the ROS production was drastically decreased (60±1%) over the 3 minute 
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Figure 4-11: Effect of TNFa on DCF fluorescence in C2C'2 myotubes. Cells were 
preincubated with DCF (5J.!M) for 15 min. Time 0 min corresponds to addition of TNFa 
(0.5ng/ml). There is a burst of ROS production 1 min affer addition of TNFa which is lost by 4 
min. Addition of MPG (1OpM) abrogates the TNFa-induced ROS as well as endogenous 
ROS in untreated cel/s. Insert is a histogram showing the right shift in DCF signal one min 
fol/owing the addition of TNFa. DCF fluorescence was normalised to the untreated group. 
*p<0.01 versus untreated control, n = 9. 
tp<O.05 versus TNFa, n = 6. 
1.4 Source of ROS production after TNFa stimulation 
A fluorescent imaging technique was used to determine the possible source 
of ROS production after TNFa stimulation. C2C12 myotubes were co-stained 
with DCFH-DA (S~M) and Mitotracker Red CM-HV<Ros (100nM). TNFa 
(O.Sng/ml) is added and the increase in intensity of fluorescence within the 
mitochondria is indicative of TNFa-induced ROS production. (Figure 4-12) 
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Figure 4-12: Mitochondria are a possible source of ROS production after TNFa 
stimulation of C2C12 myotubes. OCFH-OA (~M) fiuoresces in the presence of ROS 
(yel/ow) and Mitotracker-Red CM-H;XRos (100nM) stains the mitochondria in red. When 
TNFa (O.Sng/ml) is added and the images merged, the resulting orange depicts the TNFa-
induced ROS production, most of which appears to be in the mitochondria (arrows). 
52 
2. Exogenous TNFa exerts a direct effect on isolated 
mouse heart mitochondria: role of ROS 
2.1 Direct effect of TNFa on bioenergetic functions of isolated mouse 
heart mitochond ria 
a) Mitochondrial respiration 
TNFa (O.5ng/ml) added directly to isolated mouse heart 
mitochondria decreases State 3 respiration significantly from 
























Figure 4-13: Effect of TNFa on State 3 respiration in isolated mouse heart 
mitochondria. Addition of TNFa (0.5ng/ml) directly to isolated mouse heart mitochondria 
significantly decreases State 3 respiration. Respiration was expressed in nM of 
oxygenlminute/mg protein. 
*p<O.05 versus control, n = 9. 
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The respiratory control index (Rei) was also significantly reduced from 
7.6±1.1 (control) to 4.1±O.S (TNFa) respectively, p<O.OS. (Figure 4-14) 
8 
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Figure ~14: Effect of TNFa on the Rei of the isolated mouse heart mitochondria. The 
RCI (State 31State 4 respiration), showed a significant decrease when TNFa (0. 5ng/ml) is 
added to the isolated mouse heart mitochondria. RCI was expressed as nM of oxygen/min. 
"p<o.o.1 versus control, n = 9. 
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b) Mitochondrial proton leak 
Addition of TNFa to isolated heart mitochondria increased the proton leak 





Figure 4-15: E"ect of TNFa on Proton Leak in isolated mouse heart mitochondria. 
Oligomycin (1JJg/ml) was added to the isolated mouse heart mitochondria during State 3 
respiration , The resulting oligomycin-insensitive respiration was used to calculate the proton 
leak. Mitochondria to which TNFa (O,5ng/ml) was added showed an increase in proton leak. 
Proton leak was expressed as a percentage, 
*p<O.01 versus control, n = 9. 
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c) Inner Mitochondrial Membrane Potential 
Isolated heart mitochondria treated with TNFa (O.5ng/ml) 
exhibited a modest degree of depolarisation, 79.5±3.1 % (TNFa) 
compared with the control group, p<O.05. Results have been 
normalised against the control. (Figure 4-16) 
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Figure 4-16: Effect of exogenous TNFa on the mitochondrial inner membrane 
potential. The isolated mouse heart mitochondria were incubated with JC-1 (5IJM) for 5 
minutes at 37"C before analysis on the flow cytometer. The TNFa-treated mitochondria 
exhibited a modest degree of depolarisation as reffected by the aggregate (red) signal of JC-
1. The results have been normalised and expressed as a percentage. 
*p<O.05 versus control, n = 10. 
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cI) Mitochondrial ATP synthesis 
The rate of ATP synthesis was decreased from O.S3±O.06 
(control) to O.23±O.07 (TN Fa) with addition of TNFa (O.Sng/ml) to 
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Figure 4-17: Effect of exogenous TNFa on ATP synthesis in isolated mouse heart 
mitochondria. The addition of TNFa (O.Snglml) to isolated heart mitochondria decreased 
the rate of A TP synthesis. The concentration of A TP was expressed in JlMlmg protein. 
·p<O. OS versus control, n=6. 
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2.2 ROS scavengers abrogate the direct effect of TNFa in isolated 
mouse heart mitochondria 
a) Mitochondrial Respiration 
As described previously (Figure 3-14), treatment with TNFa 
decreases the RCI. RCI of control mitochondria was 4.4±O.2. 
Addition of ROS scavenger, NAC (30j.JM) to isolated heart 
mitochondria treated with TNFa (O.Sng/ml) abolished the effect of 
TNFa on the RCI from 1.8±O.2 for TNFa to 4.4±O.2 for 
TNFa+NAC, p<O.OS. NAC alone had no effect. (Figure 4-18) 
CTL TNFa TNFa + NAC NAC 
Figure 4-18: Effect of NAC on the RCI of TNFa-treated isolated mouse heart 
mitochondria. The addition of TNFa (0. 5ng/ml) in the presence of NAC (30f.JM) to the 
isolated mouse heart mitochondria abrogates the effect of TNFa on the respiratory control 
index (RCI). RCI was expressed as nM of oxygen/min. 
·p<fJ.01 versus TNFa, n = 6. 
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Similarly, addition of a second ROS scavenger 2-SPBN, to isolated heart 
mitochondria treated with TNFa (O .Sng/ml) abrogates the effect of TNFa on 
the RCI (1.9±O.S for TNFa and 3.9±O.6 for TNFa+2-SPBN, p<O.OS). RCI of 
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Figure 4-19: Effect of 2-SPBN on the respiratory control index of TNFa-treated mouse 
mitochondria. The addition of 2-SPBN (1OpM) in the presence of TNFa (O.5ng/ml) to the 
isolated mouse heart mitochondria abrogates the effect of TNFa on the respiratory control 
index (ReI) . ReI was expressed as nM of oxygen/min. 
*p<fJ05 versus TNFa, n = 6. 
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b) Mitochondrial Proton Leak 
ROS scavengers 2-SPBN or NAC were added to the buffer 1 
minute prior to the addition of isolated heart mitochondria. TNFa 
(O.Sng/ml) was added after a further minute. ROS scavengers 
abolished the effect of TNFa (36.6±4.1 % for TNFa and 
16.2±0.4% for TNFa+2-SPBN, p<O.01). Control mitochondria had 
a proton leak of 1S.7±O.6%. Similar results were obtained with 
NAC (not shown). 2-SPBN alone had no effect on isolated 
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Figure 4-20: Effect of ROS scavengers on TNFa-lnduced increase in Proton Leak in 
isolated mouse heart mitochondria. The isolated heart mitochondria were incubated with 
TNFa (O.5ng/ml) in the presence of 2-SPBN (1OpM) or NAG (30J1M). Oligomycin (1ug/ml) 
was added once State 3 respiration was achieved and the resulting oligomycin-insensitlve 
respiration used to calculate the proton leak. The ROS scavengers abrogated the effect of 
TNFa on proton leak. Proton leak was expressed as a percentage. 
·p<iJ.OO1 versus TNFa, n = 6. 
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2.3 Sphingolipid inhibitors abrogate the direct effect of TNFa on 
isolated mouse heart mitochondria 
a) Mitochondrial Respiration 
The mitochondria were treated withlwithout TN Fa in the presence 
of imipramine, a sphingolipid antagonist. Imipramine alone had 
no effect on isolated mitochondria. Addition of imipramine to 
TN Fa-treated mitochondria abolished the effect of TNFa on the 
RCI (1.4±O.1 for TNFa and 3.8±O.2 for TNFa+imipramine, 
p<O.01) . Control mitochondria had an RCI of 4.2±O.3 (Figure 4-
21). 
* 
eTl TNFa TNFa+IMI IMI 
Figure 4-21: Effect of imipramine on the ReI of TNFa-treated isolated mouse heart 
mitochondria. The addition of TNFa (05ng/ml) in the presence of imipramine (lMI) (10JiM) 
to the isolated mouse heart mitochondria abrogates the effect of TNFa (0.5ng/ml) on the 
respiratory control index (ReI). ReI was expressed as nM of oxygen/min. 
*p<O.01 versus TNFa, n = 6. 
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Similar results were obtained with a second sphingolipid inhibitor, 
NOE. NOE alone had no effect but the effect of TN Fa on the RCI 
was abrogated (Control 4.1 ±1 .7, TNFa 1.O±O.5, TNFa +NOE 
3.9±1.7, p<O.01). (Figure 4-22) 
TNFa lNFa+ NOE NOE 
Figure 4-22: Effect of NOE on the Rei of TNFa-treated isolated mouse heart 
mitochondria. The addition of N-oleoethanolamine (NOE) (5jJM) in the presence of TNFa 
(0.5ng/ml) to the isolated mouse heart mitochondria abrogates the effect of TNFa on the 
respiratory control index (RCI). RCI was expressed as nM of oxygen/min . 
• p<o. 05 versus TNFa. n = 6. 
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b) Mitochondrial Proton Leak 






Control mitochondria had a proton leak of 14.6±O.9%. 
Sphingolipid inhibitor, NOE or imipramine was added 
immediately prior to the addition of TNFa (O.Sng/ml) to isolated 
heart mitochondria. Addition of NOE had no effect on control 
mitochondria, but abolished the effect TNFa on the proton leak, 
reducing it from SO.4±S% for TNFa to 16.6±O.7% for TNFa+NOE, 
p<O.01. Similar results were obtained with imipramine (not 
shown). (Figure 4-23) 
CTL TNFa TNFa + NOE NOE 
Figure 4-23: Effect of Sphingolipid Inhibitors on TNFa-induced increase in Proton 
Leak in Isolated mouse heart mitochondria. The isolated heart mitochondria were 
incubated with TNFa (O.5ng/ml) in the presence of NOE (5j.JM) or imipramine (1Q.1M). 
Oligomycin (1ug/ml) was added once State 3 respiration was achieved and the resulting 
oligomycin-insensitive respiration used to calculate the proton leak. The sphingolipid 
inhibitors abrogated the effect of TNFa on proton leak. Proton leak was expressed as a 
percentage. 




The results of this study demonstrate in C2C12 myotubes that the protection 
conferred by TNFa during a simulated ischemia/reperfusion protocol is 
mediated by the production of ROS which most likely originate in the 
mitochondria. The data obtained from isolated mouse heart mitochondria 
confirm the previous study in isolated rat liver mitochondria by Busquets et 
al69 in which it was demonstrated that TNFa had a direct effect on the 
bioenergetics of the mitochondria independently of its binding to the TNFa 
cell surface receptor. In addition, the present study shows, for the first time to 
our knowledge, that this direct mitochondrial action of TNFa is mediated by 
activation of intra-mitochondrial ROS and stimulation of the sphingolipid 
pathway. 
TNFa confers cytoprotection 
Using an isolated rat heart model, Lecour et al46 previously reported that 
TNFa can mimic IPC in a dose and time response manner and that 0.5nglml 
appears to be the best dose to confer cardioprotection. Similarly, Meiring 126 
found that the same dose was required in C~12 myotubes to obtain the best 
cytoprotective effect following a simulated ischemic insult. Data obtained 
from the C2C12 myotubes in the present study confirm that 0.5ng/ml of TNFa 
confers a dramatic cytoprotective effect improving the cell viability by 60%. 
To evaluate cell viability in C2C12 myotubes both propidium iodide (PI) and 
trypan blue exclusion techniques were used. The results obtained with PI 
analysis in the ischemic preconditioning protocol conformed to those 
described previously by Minners et al. 32 Data with the trypan blue technique 
did not differ from PI showing that both methods are validated to measure 
cell viability. 
Previous evidence presented by Minners et al32 in ischemic or 
pharmacologically preconditioned cells showed that the inner mitochondrial 
membrane of cells was depolarised and oxygen consumption was increased 
prior to the simulated ischemic insult. The data presented in this thesis 
conform to that of Minners et al32 for IPC and in addition, show that 
membrane potential and cellular respiration were restored to normal levels 
immediately post simulated ischemia, in both IPC and TNFa groups. 
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TNFa-induced cytoprotection is mediated by ROS 
The role of ROS in mediating preconditioning is becoming increasingly 
appareneo It has been reported that low doses of ROS can mimic ischemic 
preconditioning 123 and that the ROS scavenger, MPG. can abrogate a single 
episode of preconditioning.94 ROS may protect via activation of different 
kinases such as protein kinase C.94 or by acting on the mitochondrial 
permeability transition pore. 124 Using an isolated rat heart model, Lecour et 
al125 showed, that perfusion of TNFa (O.5ng/ml) was associated with an 
increase of ROS and that the cardioprotective effect of TNFa was blocked in 
the presence of MPG. This provides firm evidence for the production and a 
role of ROS in TNFa .. induced cardioprotection. The source of ROS and their 
mechanism of action, however, remained to be delineated. 
The data obtained from C2C12 myotubes in the present study, confirmed the 
production and role of ROS in TNFa-induced cytoprotection as addition of 
ROS scavengers abolished this cytoprotective effect. In addition, after TN Fa 
stimulation of the cells, an increase in ROS production was seen. This 
provided firm evidence that it was the reactive oxygen species generated by 
TNFa which conferred the protection seen in the simulated 
ischemialreperfusion protocol. 
TNFa generates ROS within the mitochondria 
Mitochondria have been identified as a major source of ROS production.127 
Vanden Hoek et al 70 used chick cardiomyocytes to show that ROS originate 
from the mitochondria during a hypoxic insult. This experiment demonstrated 
that ROS were generated during the hypoxic preconditioning rather than 
during the reoxygenation penod. Using the same model of chick 
cardiomyocytes, Vanden Hoek et al70 showed that mitochondrial ROS can 
activate signalling cascades involved in IPC. Goossens et al107 provided firm 
evidence on the induction of ROS formation in mitochondria upon TNFa 
stimulation in L929 cells. In a study by Corda et al 110 it was demonstrated 
that TNFa induced a rapid increase in mitochondrial ROS production in 
human endothelial cells. 
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By co-staining with Mitotracker Red CM-H2XRos and DCFH-DA and using a 
fluorescent imaging technique, we have shown that the ROS generated by 
the protective dose of TNFa in ~C12 myotubes most likely originated within 
the mitochondria. 
Although a" previous papers have shown a deleterious effect of ROS 
produced in the mitochondria following a TNFa stimulation,107.109.130 we have 
demonstrated that ROS has a protective effect when TNFa was used at a 
low concentration. 
TNFa has a direct effect on the bioenergetic functions of the heart 
mitochondria 
A mitochondrial binding protein as we" as an intrace"ular trafficking pathway 
for TNFa has recently been discovered.40•69 Busquets et al69 showed that the 
addition of a low concentration of TNFa to isolated mouse liver mitochondria 
decreased the respiratory control index (RCI) of the mitochondria suggesting 
that TN Fa acted directly on the mitochondria. 
Isolated mouse heart mitochondria were used in the present study as a 
model to determine whether TNFa could exert a direct effect on heart 
mitochondria, independently of its binding to the TNFa cell-surface receptors. 
One limitation of this study is the question of mitochondrial purity. Various 
techniques such as LDH release into the cytosol69 or Percoll gradient 
centrifugation109 have been used to determine mitochondrial purity. However, 
these were done in liver mitochondria where a reasonable amount of 
mitochondria were obtained. In contrast, minute quantities of mitochondria 
are obtained from a mouse heart. Percoll centrifugation is therefore 
impossible. Likewise the amount of LDH release into the cytosol would give 
erroneous results firstly, because of the scarcity of mitochondria and 
secondly. as a result of relatively low centrifugation speeds, the cytosolic 
fraction could be contaminated by the mitochondrial fraction. High speed 
centrifugation is also detrimental for bioenergetic stUdies as although "pure" 
mitochondria are obtained, they are no longer actively respiring and the 
bioenergetics are therefore greatly compromised, with the RCI dropping to 
below 1 (RCI ~ 3 is accepted as a viable preparation). A technique using two 
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different centrifugal speeds was therefore chosen. The first centrifugation at a 
low speed (2930 rpm) is sufficient to pellet the larger intracellular constituents 
without damaging the mitochondria. The supernatant is carefully collected 
and the mitochondria are pelleted by centrifuging at 4500 rpm. The cytosolic 
fractions, having a much lower mass than the mitochondria, are not pelleted 
but remain in this second supernatant and are discarded, leaving the 
mitochondrial pellet. A relatively "pure" mitochondrial preparation without 
compromising the bioenergetics of the mitochondria is obtained with this 
technique. 
Data obtained from the present study, confirm the decrease in State 3 
respiration and RCI, as shown in the liver mitochondria by Busquets et al.69 
In addition, it was shown for the first time in isolated heart mitochondria, that 
membrane potential and rate of ATP synthesis were decreased when the 
mitochondria were stimulated with a low dose of TNFa. These mitochondria 
exhibited what appeared to be a less efficient energetic state and may have 
been "preconditioned" to withstand a more severe insult. However, when 
ROS scavengers, NAC and 2-SPBN were added prior to the TNFa stimulus 
these effects were abolished. This confirmed that TNFa had a direct effect on 
the bioenergetics of isolated heart mitochondria and provided strong 
evidence that this effect was mediated via mitochondrial ROS. Interestingly, 
sphingolipid inhibitors, imipramine and NOE also abrogated the effect of 
TNFa on isolated heart mitochondria, suggesting the involvement of the 
sphingolipid pathway. It is known that there is a mitochondrial pool of 
ceramide128.TNFa has been shown to increase the intra-mitochondrial levels 
of cerami de through the activation of at least two pathways: one is mediated 
by sphingomyelinase and the other is dependent on ceramide synthesis.129 
Because ceramide is known to generate ROS,109.110 it is appropriate to 
stipulate that TNFa activates ROS generation via the ceramide pathway in 
the model of isolated heart mitochondria used in this study. 
Conclusion 
TNFa is a naturally occurring cytokine produced by a wide variety of cell 
types. Depending on concentration and time conditions, TNFa can have both 
deleterious and beneficial effects. Many authors have shown the deleterious 
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effects of TNFa, such as the elevated circulating levels of TNFa in severe 
chronic heart failure and lethal myocarditis in mice with cardiac-specific 
overexpression of TN Fa.42-45In contrast, Lecour et al46 have shown that low 
doses of TNFa can be beneficial in isolated rat heart and other research has 
shown similar benefits.50 Similarly, the beneficial or deleterious effects of 
reactive oxygen species appear to be concentration and time-dependent, 
with many authors showing that large amounts of ROS are present during 
ischemiclreperfusion injury.87-89 Conversely, the presence of small amounts 
of ROS have beneficial effects.71 •81 
The data obtained from C>.!C12 myotubes show that ROS generated by TNFa 
in a low dose is cytoprotective during ischemialreperfusion. This study also 
demonstrated that TNFa-induced ROS originated mosUy within the 
mitochondria of the myotubes. Data obtained from the isolated heart 
mitochondria confinn that exogenous TNFa has a direct effect on 
mitochondria. In addition, it has been shown for the first time that the direct 
effect of TNFa on the mitochondrial bioenergetics is abolished by ROS 
scavengers and sphingolipid inhibitors, providing a link between intra-
mitochondrial ROS generation and the activation of sphingolipids. However, 
the link between cytoprotection in ischemialreperfusion and the direct 
mitochondrial action of TNFa has yet to be established. 
The changes seen in mitochondrial bioenergetics after direct stimulation with 
TNFa reflect mitochondrial function immediately prior to the index 
ischemialreperfusion insult. The results obtained from isolated heart 
mitochondria demonstrate for the first time, that the TN Fa-treated 
mitochondria exhibit features consistent with respiratory uncoupling, as 
shown by the depolarisation of the inner mitochondrial membrane potential 
and the decrease in rate of ATP synthesis. Thus, these mitochondria appear 
to have a less efficient bioenergetic state than those that have not been 
"preconditioned" with TNFa, suggesting that uncoupling of oxidation from 
phosphorylation by preconditioning would make the mitochondria more 
resilient to a lethal insult. Together, the data from the cells and the isolated 
heart mitochondria strongly suggest that treatment with a low concentration 
of TNFa improves the tolerance of mitochondria to subsequent lethal 
ischemia. We speculate that this could be mediated by the production of 
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intra-mitochondrial ROS and subsequent activation of intra-mitochondrial 
sphingolipids. 
Future direction 
The exact effect of uncoupling oxidative phosphorylation in preconditioning 
has not yet been established. The generation of ROS by the mitochondria as 
signalling intermediates in the preconditioning program has been postulated 
by Vanden Hoek et al,70 Forbes et al,71 and Yao et aI.135,136 In contrast, 
Carmody et al137 and Halmosi et al136 showed that a more robust generation 
of ROS by mitochondria could have detrimental effects on cellular survival 
and integrity. Previous data have shown that there may be a potential role for 
enhanced mitochondrial uncoupling as a regulatory process which may limit 
excessive ROS generation in the context of ischemia.14O-142 The data 
presented in this study demonstrate that the intra-mitochondrial ROS 
generated by the direct action of a low dose of TNFa on the mitochondria 
stimulates the ceramide pathway. It is possible to speculate that this may be 
a "pro-survival" pathway which can confer cytoprotection during 
ischemia/reperfusion. However. the data on the isolated heart mitochondria 
were obtained under normoxic conditions. Future research plans include the 
establishment of a mitochondrial model of "ischemialreperfusion" to explore 
whether the stimulation of ROS production and activation of sphingolipids in 
the mitochondria by TNFa, independently of its binding to TNFa cell surface 
receptors, can have a protective effect during ischemia/reperfusion. In 
addition. the establishment of this model will pave the way for the 
investigation of other preconditioning triggers and their signalling pathways 
during ischemialreperfusion. 
In conclusion, a new approach to the study of the effects of TNFa on the 
heart may be initiated from the present work. New strategies and targets may 
be identified to enable the treatment of cardiac disease in the future by 
understanding the mechanisms involved in the direct signalling pathway 
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